Skye Bioscience logo
Skye Bioscience
SKYE | NASDAQ
Chart Builder DCF Calculator
$1.06
-$0.03 (-2.75%)
At close: Nov 16, 2026, 4:00 PM ET
$1.08
+$0.02 (+1.82%)
After-hours: Nov 16, 2026, 7:59 PM ET

Skye Bioscience Company Profile

Company profile explained

Company Profile

Skye Bioscience, Inc., a clinical-stage biotechnology company, focuses on developing molecules that modulate G-protein-coupled receptors (GPCRs) to treat obesity, overweight, and metabolic diseases. Its lead product candidate is nimacimab, a peripherally restricted negative allosteric modulating antibody targeting cannabinoid receptor 1, a key GPCR involved in metabolic regulation. The company was formerly known as Emerald Bioscience, Inc. and changed its name to Skye Bioscience, Inc. in January 2021. Skye Bioscience, Inc. is headquartered in San Diego, California.

Key Executives

Name Position
Punit S. Dhillon President, CEO, Principal Financial & Accounting Officer & Director
John Sharp CFO and Principal Financial & Accounting Officer

Latest SEC Filings

Date Type Title
Oct 28, 2026 PRER14A Filing
Oct 26, 2026 PREM14A Filing
Oct 14, 2026 SC 13G Statement of acquisition of beneficial ownership b...
Sep 24, 2026 4 Filing
Sep 24, 2026 SC 13D/A [Amend] Filing
Sep 24, 2026 4 Filing
Sep 18, 2026 4 Filing
Sep 18, 2026 4 Filing
Sep 11, 2026 DEFA14A Filing
Sep 11, 2026 8-K Current Report
View All SEC Filings ➞
Skye Bioscience
Skye Bioscience logo
Country United States
IPO Date Jan 6, 2015
Industry Biotechnology
Sector Healthcare
Employees 2
CEO Punit Dhillon

Contact Details

11250 El Camino Real San Diego, California 92130 United States

Stock Details

Ticker Symbol SKYE
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001516551
CUSIP Number 83086J309
ISIN Number US83086J3095
SIC Code 2834

© 2026 bestshares.com. All rights reserved.

All data is for informational purposes only. bestshares.com is not a broker, dealer, or registered investment adviser, and nothing on this site is a recommendation to buy or sell any security.